US FDA to decide fate of Genentech's pertuzumab by 8 June
This article was originally published in Scrip
The US FDA will make a decision by 8 June on whether to approve Genentech's HER-dimerisation inhibitor pertuzumab as a treatment in combination with the firm's Herceptin (trastuzumab) plus docetaxel chemotherapy for patients with HER2-positive metastatic or locally recurrent, unresectable breast cancer who have not received previous treatment or whose disease has relapsed after adjuvant therapy, the South San Francisco-based company said.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.